Oligomers of prostaglandin B1 inhibit in vitro phospholipase A2 activity.
Oligomers of prostaglandin B1 inhibited phospholipase A2 extracted from human neutrophils in a dose-dependent manner (IC50 = 5 microM), while the monomer was not inhibitory at concentrations of 10 microM or less. The inhibitory activity of PGB1 oligomers increased with increasing polymer size; PGB dimer had approximately one-half the maximal inhibitory activity of PGBx, while a trimer was almost as inhibitory as a tetramer and PGBx (n = 6). PGBx as an oil or as a water-soluble sodium-salt-inhibited Ca2(+)-dependent phospholipase A2 from snake venom, bovine pancreas, human neutrophil and platelet, human synovial fluid, and human sperm with IC50 values ranging from 0.5-7.5 microM. Inhibition was independent of added Ca2+ and was independent of substrate phospholipid concentration. Interaction of purified snake venom phospholipase A2 (Naja mocambique) with PGBx resulted in dose-dependent quenching of the enzyme's tryptophan fluorescence; 50% quench was noted with a molar ratio of PGBx/enzyme of 1.5. Inhibition of phospholipase A2 activity by PGBx was relieved in a dose-dependent manner by either defatted or untreated bovine serum albumin. PGBx is a potent in vitro inhibitor of a wide spectrum of phospholipases A2, and as illustrated in the accompanying paper, has profound inhibitory effects on arachidonic acid mobilization in human neutrophils and vascular endothelial cells. Modulation of cellular and extracellular phospholipases A2, and the bioactive transmitters generated by this catalytic event, may be a basic mechanism by which oligomers of prostaglandin B1 exert their reported membrane-protective effects.
Franson
R C
RC
Department of Biochemistry and Molecular Biophysics, Virginia Commonwealth University, Richmond 23298.
Rosenthal
M D
MD
D001792:Blood Platelets / Q000201:enzymology; D004546:Elapid Venoms / Q000032:analysis; D006801:Humans; D046911:Macromolecular Substances; D008297:Male; D009504:Neutrophils / Q000201:enzymology; D010740:Phospholipases / Q000037:antagonists & inhibitors*; D010741:Phospholipases A / Q000037:antagonists & inhibitors*; D054467:Phospholipases A2; D011108:Polymers / Q000494:pharmacology*; D011453:Prostaglandins / Q000494:pharmacology*; D011456:Prostaglandins B / Q000494:pharmacology*; D011465:Prostaglandins, Synthetic; D012710:Serum Albumin, Bovine / Q000494:pharmacology; D013094:Spermatozoa / Q000201:enzymology; D013329:Structure-Activity Relationship; D013582:Synovial Fluid / Q000201:enzymology
D004546:Elapid Venoms; D046911:Macromolecular Substances; D011108:Polymers; D011453:Prostaglandins; D011456:Prostaglandins B; D011465:Prostaglandins, Synthetic; C034467:prostaglandin B1; D012710:Serum Albumin, Bovine; C024303:prostaglandin Bx; D010740:Phospholipases; D010741:Phospholipases A; D054467:Phospholipases A2